Sarah B. Goldberg, MD, MPH | Authors


Considering the Role of Clinical Trials for Patients With Molecularly Altered Lung Cancers

September 03, 2019

Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as EGFR, ALK, BRAF,ROS1, or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.